Staar Surgical CO 10-Q quarterly reports

STAAR Surgical Company's Q2 2026 results show a significant increase in net sales and a return to net income, driven by strong performance in China and improved gross margins.

STAAR Surgical Company announced a significant increase in net sales and a return to profitability in the first quarter of 2026, largely driven by robust performance in China.

STAAR Surgical Company reported increased net sales and gross profit for Q3 2025, driven by China sales and cost reductions, while facing a significant year-to-date net loss and a proxy contest over its proposed $28.00 per share acquisition by Alcon.

STAAR Surgical Company reported a significant net loss and revenue decline in Q2 2025, primarily driven by reduced sales in China, while announcing a definitive merger agreement with Alcon for $28.00 per share.

STAAR Surgical's Q1 2025 net sales plummeted 45% year-over-year due to a significant drop in China sales and restructuring initiatives.

STAAR Surgical Company's Q3 2024 results show a 10.3% increase in net sales driven by a 9.9% rise in ICL sales, despite some foreign currency headwinds.

STAAR Surgical Company announced a 7% increase in net sales for the second quarter of 2024, driven primarily by growth in ICL sales.

STAAR Surgical's first quarter saw a 5.2% increase in net sales, driven by ICL growth, but a net loss due to higher operating expenses.